Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2015 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Dyne Therapeutics, Inc. | 16 | Q2 2024 | 37.4% |
Allogene Therapeutics, Inc. | 16 | Q2 2024 | 42.5% |
Kronos Bio, Inc. | 15 | Q2 2024 | 20.4% |
Centessa Pharmaceuticals plc | 13 | Q2 2024 | 39.4% |
Kinnate Biopharma, Inc. | 13 | Q4 2023 | 29.3% |
Praxis Precision Medicines, Inc. | 12 | Q3 2023 | 33.2% |
LianBio | 9 | Q4 2023 | 12.1% |
Homology Medicines, Inc. | 9 | Q3 2022 | 5.2% |
Oyster Pt Pharma Inc | 5 | Q3 2021 | 10.3% |
Assembly Biosciences, Inc. | 4 | Q2 2021 | 4.6% |
View Vida Ventures Advisors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-07-23 |
13F-HR | 2024-07-10 |
13F-HR | 2024-04-12 |
13F-HR | 2024-01-05 |
13F-HR | 2023-10-03 |
13F-HR | 2023-07-19 |
13F-HR | 2023-04-13 |
13F-HR | 2023-02-08 |
13F-HR | 2022-10-05 |
13F-HR | 2022-07-15 |
View Vida Ventures Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.